Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Arch Pediatr ; 18(9): 1016-8, 2011 Sep.
Artículo en Francés | MEDLINE | ID: mdl-21733665

RESUMEN

Management of bone and joint infections in children associates early appropriate antibiotic therapy against Staphylococcus aureus and Kingella kingae and, if necessary, surgical drainage of abscess or septic arthritis. In 2007, the Paediatric Infectious Diseases Group of the French Society of Paediatrics (GPIP) proposed guidelines for antibiotherapy in acute and non-complicated cases, with an intravenous therapy during 4 to 7 days followed by oral therapy during 3 weeks.


Asunto(s)
Antibacterianos/uso terapéutico , Artritis Infecciosa/tratamiento farmacológico , Kingella kingae , Infecciones por Neisseriaceae/tratamiento farmacológico , Infecciones Estafilocócicas/tratamiento farmacológico , Staphylococcus aureus , Artritis Infecciosa/microbiología , Artritis Infecciosa/cirugía , Niño , Humanos , Kingella kingae/aislamiento & purificación , Pruebas de Sensibilidad Microbiana , Infecciones por Neisseriaceae/complicaciones , Infecciones por Neisseriaceae/cirugía , Osteomielitis/tratamiento farmacológico , Guías de Práctica Clínica como Asunto , Infecciones Estafilocócicas/complicaciones , Infecciones Estafilocócicas/cirugía , Staphylococcus aureus/aislamiento & purificación , Resultado del Tratamiento
2.
Arch Pediatr ; 15(3): 245-52, 2008 Mar.
Artículo en Francés | MEDLINE | ID: mdl-18321692

RESUMEN

UNLABELLED: Only few drugs for uncomplicated Plasmodium falciparum malaria are available in children. Atovaquone-proguanil is a recent antimalarial drug licensed in France for the uncomplicated P. falciparum malaria in adults. Few paediatric studies have evaluated atovaquone-proguanil in children for uncomplicated malaria in endemic area, but no study have evaluated this treatment for imported malaria. OBJECTIVE: To evaluate treatment by atovaquone-proguanil for uncomplicated and imported P. falciparum malaria in children. METHODS: We retrospectively evaluated the tolerance and the efficacy of atovaquone-proguanil in the children admitted in Robert-Debré Hospital (Paris) for a P. falciparum malaria. From January 2004 to December 2005, 48 children with a median age of 7,5 years (IQR 4-11) were treated with atovaquone-proguanil for a uncomplicated P. falciparum malaria, except for 5 children who had an isolated hyperparasitemia greater or equal to 5%. RESULTS: Atovaquone-proguanil was stopped for 3/48 children because of vomiting. Fever resolved in all the children between Day 3 and 7, following the beginning of the treatment. One child, with a favourable outcome, had a positive parasitemia at Day 4 equal to the initial parasitemia (0,1%). No late therapeutic failure was observed among the 24 children evaluated up to one month after starting treatment. CONCLUSION: Atovaquone-proguanil is an efficient and well-tolerated antimalarial treatment for uncomplicated P. falciparum malaria in children. The risk of vomiting should lead to a systematic initial hospitalisation of children treated with atovaquone-proguanil.


Asunto(s)
Antimaláricos/uso terapéutico , Atovacuona/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Proguanil/uso terapéutico , Animales , Proteína C-Reactiva/metabolismo , Niño , Preescolar , Combinación de Medicamentos , Quimioterapia Combinada , Tolerancia a Medicamentos , Hospitales Universitarios , Humanos , Pruebas de Función Hepática , Paris , Plasmodium falciparum , Estudios Retrospectivos , Viaje
4.
JPEN J Parenter Enteral Nutr ; 15(5): 551-5, 1991.
Artículo en Inglés | MEDLINE | ID: mdl-1942469

RESUMEN

A retrospective study in 38 children (1 day to 7 years) on total parenteral nutrition (TPN) (1 month-24 months) with a central venous catheter (CVC) evaluated the contribution of two-dimensional echocardiography (2D) and M-mode in the follow-up of CVC location and early diagnosis of related complications. Fifty examinations were performed routinely in 21 patients (group I) and 40 in 17 patients for sepsis of the CVC or clinical suspicion of thrombosis (group II). The tip of the CVC was located in the upper right atrium in 17 cases (45%), superior vena cava in 14 cases (37%), jugular or subclavian vein in 5 cases (13%), and was not visualized in 2 cases (15%). In group I, 2D was normal in 19 cases, and catheter thrombosis suspected in 2 was not confirmed by digital angiography (DA). In group II, 2D was normal in 11 cases. In 6 patients, subxiphoid and suprasternal planes identified superior vena cava thrombus in the right atrium (DA confirmed the diagnosis in 2). In 2 pulmonary embolism occurred (1 case died); the remaining patients were successfully treated by medical therapy and removal of the catheter. Echocardiography is a useful noninvasive technique to control CVC tip location and follow-up. In this study, the sensitivity of cardiac thrombus detection by echocardiography was 100% and the specificity 93%; this method appeared, therefore, appropriate for early detection of cardiac thrombosis in pediatric patients on TPN.


Asunto(s)
Cateterismo Venoso Central , Ecocardiografía , Nutrición Parenteral Total , Cateterismo Venoso Central/efectos adversos , Preescolar , Estudios de Evaluación como Asunto , Humanos , Lactante , Nutrición Parenteral Total/efectos adversos , Factores de Riesgo , Tromboflebitis/diagnóstico por imagen , Tromboflebitis/etiología , Vena Cava Superior/diagnóstico por imagen
5.
Arch Fr Pediatr ; 46(8): 595-7, 1989 Oct.
Artículo en Francés | MEDLINE | ID: mdl-2604514

RESUMEN

Two children with the coexistence of long segment Hirschsprung's disease, ganglioneuroblastoma with Ondine's curse in one case and autonomic nervous system impairment in the other are presented. All lesions may be related to aberrations of neural crest cell growth, their migration, or differentiation. A genetic etiology, and the link between Hirschsprung's disease and multiple endocrine adenomatosis is discussed. The combination of Hirschsprung's disease and a neurocristopathy strongly suggests that exploration of the autonomic nervous system and APUD system be carried out.


Asunto(s)
Enfermedades del Sistema Nervioso Autónomo/complicaciones , Ganglioneuroma/complicaciones , Enfermedad de Hirschsprung/complicaciones , Cresta Neural/anomalías , Enfermedades del Sistema Nervioso Autónomo/embriología , Femenino , Ganglioneuroma/embriología , Enfermedad de Hirschsprung/embriología , Humanos , Recién Nacido , Masculino , Cresta Neural/embriología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA